FDA Panel Supports Rx-to-OTC Switch of Progestin-Only Birth Control Pill
A decision on the OTC oral contraceptive pill is expected later this year.
Diagnosis & Disease Information
Emzahh Gets FDA Approval for Pregnancy Prevention
Emzahh is an AB-rated generic equivalent of Ortho Micronor.
FDA Allows Certified Retail Pharmacies to Dispense Mifepristone
Mifepristone is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
Case Study: 2-Rod Subdermal Contraceptive Implant in a Recent Immigrant
Case involving a 2-rod subdermal contraceptive implant mistaken for a 1-rod device demonstrates the importance of delivering culturally competent care.
FDA Panel Meeting Scheduled to Discuss Rx-to-OTC Switch of Oral Contraceptive Opill
Opill contains 0.075 mg of norgestrel, a single active steroid ingredient.
Rx-to-OTC Switch Application Submitted for Oral Contraceptive Opill
If approved, Opill would be the first OTC oral contraceptive pill available without a prescription.
Some Pharmacies Limiting Morning-After Pill Sales to Avoid Potential Shortage
Temporary purchase limits aim to ensure ‘equitable access and consistent supply on store shelves’.
At-Home Test Helps With Birth Control Selection by Identifying Risk for Side Effects
Through hormone measurements and genetic analysis, the test can identify whether an individual is at increased risk for certain birth control side effects.
Ob/Gyn Update: Lack of Postpartum Contraceptive Use, Pelvic Pain Guidelines, and Infection Risk With Alternative Birth Practices
Recent OB/Gyn updates include underuse of contraceptives after giving birth, new guidelines on postpartum pelvic girdle pain, and infection risk with alternative birth practices.
Oral Contraceptive With Novel Estrogen Under FDA Review
The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP).
- Loading...
Loading...
Next post in News
Loading... 
Loading...